+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07431827

Study of Adjuvant MK-1084 with Pembrolizumab and Berahyaluronidase Alfa Versus Placebo in Resected Stage IIA-IIIB KRAS G12C-mutant Non-small Cell Lung Cancer

Led by Merck Sharp & Dohme LLC · Updated on 2026-11-02

400

Participants Needed

120

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of adjuvant calderasib combined with subcutaneous pembrolizumab and berahyaluronidase alfa MK-3475A compared to adjuvant placebo plus MK-3475A in participants with completely resected stage IIA-IIIB N2, KRAS G12C-mutant non-small cell lung cancer. This phase 3, randomized, double-blind study focuses on participants who have previously received either neoadjuvant pembrolizumab plus chemotherapy or adjuvant chemotherapy. The main goal is to compare disease-free survival between the treatment groups. Participants are assigned to one of two groups one group receives daily calderasib and MK-3475A every six weeks for up to nine doses, while the other group receives a daily placebo plus MK-3475A on the same schedule. The study treatments are administered as oral tablets for calderasib or placebo, and subcutaneous injections for MK-3475A. Treatment continues for up to nine doses or until disease progression or other criteria are met. During the study, participants will undergo regular assessments including imaging scans such as contrast-enhanced chest or abdomen CT or MRI to confirm no evidence of disease before starting treatment. Researchers will monitor disease-free survival up to approximately 11 years, along with overall survival, lung cancer specific survival, distant metastasis-free survival, quality of life measures, and safety outcomes. Adverse events and treatment discontinuations will be tracked for up to 13.5 years, ensuring long-term safety and efficacy monitoring.

CONDITIONS

Brief Title

MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

Research Team

T

Toll Free Number

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here